Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With GlioblastomaLARKSPUR, Calif. (BUSINESS WIRE) #GBMAGILE Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and V.
The Ontario Brain Institute is playing a key role in open science and brain health research with the release of new clinical data that will help scientists around the world advance investigations into pediatric neurological conditions.
/PRNewswire/ - Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic therapies for use in mental health treatment,.
/PRNewswire/ - Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic therapies for use in mental health treatment,.